EUVIMEDSkopri EUVIMED
Open access

A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling

Wei Wei iD, Ondrej Blaha iD, Denise Esserman iD, Daniel Zelterman, Michael Kane iD, Rachael Liu iD, Jianchang Lin iD

Statistics in Medicine · 2024

DOI: 10.1002/sim.10077 ↗

At a glance

Journal article in Statistics in Medicine, 2024. Written by Wei Wei and 6 co-authors. Institution: Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA. Major MEDLINE topics: Bayes Theorem, Computer Simulation, Randomized Controlled Trials as Topic, Models, Statistical. Cited 5 times so far (Crossref); 23 references. The full text is freely available in PubMed Central. Funded by: NIDCR NIH HHS, NCATS NIH HHS, NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Enrolling patients to the standard of care (SOC) arm in randomized clinical trials, especially for rare diseases, can be very challenging due to the lack of resources, restricted patient population availability, and ethical considerations. As the therapeutic effect for the SOC is often well documented in historical trials, we propose a Bayesian platform trial design with hybrid control based on the multisource exchangeability modelling (MEM) framework to harness historical control data. The MEM approach provides a computationally efficient method to formally evaluate the exchangeability of study outcomes between different data sources and allows us to make better informed data borrowing decisions based on the exchangeability between historical and concurrent data. We conduct extensive simulation studies to evaluate the proposed hybrid design. We demonstrate the proposed design leads to significant sample size reduction for the internal control arm and borrows more information compared to competing Bayesian approaches when historical and internal data are compatible.

Subjects

MeSH terms (MEDLINE)

Bayes TheoremComputer SimulationRandomized Controlled Trials as TopicModels, StatisticalHumansSample SizeResearch DesignAdaptive Clinical Trials as Topic

Author keywords

Bayesian adaptive designshistorical datainformative priorplatform trialrare disease

Authors and institutions

  • Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
  • Statistical & Quantitative Sciences, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.

ORCID profiles: Wei Wei, Ondrej Blaha, Denise Esserman, Michael Kane, Rachael Liu, Jianchang Lin

Funding

  • NIDCR NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Cite

APA

Wei, W., Blaha, O., Esserman, D., Zelterman, D., Kane, M., Liu, R., & Lin, J. (2024). A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics in Medicine. https://doi.org/10.1002/sim.10077

Vancouver

Wei W, Blaha O, Esserman D, Zelterman D, Kane M, Liu R, et al. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics in Medicine. 2024. doi:10.1002/sim.10077

BibTeX
@article{Wei2024,
  author = {Wei, Wei and Blaha, Ondrej and Esserman, Denise and Zelterman, Daniel and Kane, Michael and Liu, Rachael and Lin, Jianchang},
  title = {A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10077}
}
Start for free →